Metabolomic Signatures for Predicting, Diagnosing, and Prognosing Various Diseases Including Cancer

Abstract

A system and method for using new biomarkers to assess individual diseases is provided. In one embodiment of the present invention, absolute quantification of annotated metabolites by mass spectrometry is used to identify certain biomarkers and derivatives thereof (i.e., signatures), which are then used to screen for, diagnose, predict, prognose, and treat various diseases, including, but not limited to, breast cancer, ovarian cancer, colorectal cancer, pancreatic cancer, and acute graft-versus-host disease.

What is claimed is: 
     
         1 . A method for assessing a human patient for pancreatic cancer, comprising:
 using a technology selected from chromatography, spectroscopy, and spectrometry to quantify a plurality of metabolites included in a blood sample obtained from said human patient, including at least Dodecanedioylcarnitine and Lysophosphatidylcholine;   normalizing data values obtained in the quantification of at least said Dodecanedioylcarnitine and said Lysophosphatidylcholine;   comparing at least a result of an equation comprising at least a first ratio of said Dodecanedioylcarnitine and said Lysophosphatidylcholine, as normalized, to at least one predetermined value to both diagnose said human patient for said pancreatic cancer and determine a prognosis for said human patient, said at least one predetermined value being a second result of said equation using normalized and quantified metabolites including at least Dodecanedioylcarnitine and Lysophosphatidylcholine from a second sample taken from a second human patient with at least a known diagnosis for pancreatic cancer;   wherein said diagnosis for said human patient includes at least whether said human patient has pancreatic cancer and said prognosis for said human patient includes at least a risk factor associated with said pancreatic cancer, said risk factor being a score on a linear scale that indicates at least one of a survival rate for said human patient and a response to treatment for pancreatic cancer.   
     
     
         2 . The method of  claim 1 , wherein said step of quantifying and normalizing said Lysophosphatidylcholine further comprises the step of quantifying and normalizing Lysophosphatidylcholine with acyl residue heptadecanoic acid. 
     
     
         3 . The method of  claim 1 , wherein said first ratio is said Dodecanedioylcarnitine to said Lysophosphatidylcholine. 
     
     
         4 . The method of  claim 1 , wherein said first ratio is said Lysophosphatidylcholine to said Dodecanedioylcarnitine. 
     
     
         5 . The method of  claim 1 , further comprising the steps of quantifying and normalizing at least one of Propenoylcarnitine and Hexenoylcarnitine and comparing at least a second result of a second equation comprising at least a second ratio of said at least one of said Propenoylcarnitine and said Hexenoylcarnitine and said Dodecanedioylcarnitine, as normalized, to at least one other predetermined value to at least determine said prognosis for said human patient, wherein said at least one other predetermined value is another result of said second equation using normalized and quantified metabolites including at least Dodecanedioylcarnitine, Lysophosphatidylcholine, and at least one of Propenoylcarnitine and Hexenoylcarnitine from said second sample taken from said second human patient. 
     
     
         6 . The method of  claim 1 , wherein said step of normalizing said data values further comprises using at least a log-transformation to normalize at least said Dodecanedioylcarnitine and said Lysophosphatidylcholine. 
     
     
         7 . The method of  claim 1 , wherein said linear scale indicates at least a a response to treatment for pancreatic cancer. 
     
     
         8 . The method of  claim 1 , wherein said linear scale indicates at least a survival rate of said human patient from said pancreatic cancer. 
     
     
         9 . The method of  claim 1 , wherein said linear scale further indicates at least a relapse rate of said pancreatic cancer. 
     
     
         10 . The method of  claim 1 , wherein said linear scale identifies a degree of pancreatic cancer, said degree being one of non-invasive, invasive, metastatic, and lethal. 
     
     
         11 . The method of  claim 1 , wherein said response to treatment is a viability of at least one treatment in said human patient for said pancreatic cancer. 
     
     
         12 . A system for assessing a human patient for pancreatic cancer, comprising:
 a computing system comprising at least one memory device for storing machine readable instructions configured to perform the steps of:
 receive a plurality of quantified metabolites from a sample provided by said human patient, including at least Dodecanedioylcarnitine and Lysophosphatidylcholine, said quantification being performed using a technology selected from one of chromatography, spectroscopy, and spectrometry; 
 normalize said plurality of quantified metabolites; 
 compare at least a result of an equation comprising at least a first ratio of said Dodecanedioylcarnitine and said Lysophosphatidylcholine, as normalized, to at least one predetermined value to determine at least one level of similarity therebetween, said at least one predetermined value being a second result of said equation using normalized and quantified metabolites from a second sample taken from a second human patient with at least a known diagnosis for pancreatic cancer; and 
 use said at least one level of similarity to determine a diagnosis and a prognosis for said human patient regarding said pancreatic cancer; 
   wherein said diagnosis includes at least whether said human patient has pancreatic cancer and said prognosis includes at least a risk factor for said human patient associated with said pancreatic cancer, said risk factor being a score on a scale that indicates at least one of a rate of survival for said human patient and a response to treatment for pancreatic cancer.   
     
     
         13 . The system of  claim 12 , wherein said Lysophosphatidylcholine comprises Lysophosphatidylcholine with acyl residue heptadecanoic acid. 
     
     
         14 . The system of  claim 13 , wherein said Dodecanedioylcarnitine is a numerator and said Lysophosphatidylcholine with acyl residue heptadecanoic acid is a denominator in said first ratio. 
     
     
         15 . The system of  claim 13 , wherein said Lysophosphatidylcholine with acyl residue heptadecanoic acid is a numerator and said Dodecanedioylcarnitine is a denominator in said first ratio. 
     
     
         16 . The system of  claim 12 , wherein said quantified metabolites further include Propenoylcarnitine, and said machine readable instructions are further configured to compare at least a second result of a second equation comprising at least a second ratio of said Propenoylcarnitine and said Dodecanedioylcarnitine to at least one other predetermined value to determine a level of similarity therebetween, said level of similarity being used at least to determine said prognosis for said human patient, wherein said at least one other predetermined value is another result of said second equation using normalized and quantified metabolites including at least Dodecanedioylcarnitine, Lysophosphatidylcholine, and Propenoylcarnitine from said second sample taken from said second human patient. 
     
     
         17 . The system of  claim 12 , wherein said quantified metabolites further include Hexenoylcarnitine, and said machine readable instructions are further configured to compare at least a second result of a second equation comprising at least a second ratio of said Hexenoylcarnitine to said Dodecanedioylcarnitine to at least one other predetermined value to determine a level of similarity therebetween, said level of similarity being used to at least determine said prognosis for said human patient, wherein said other predetermined value is another result of said second equation using normalized and quantified metabolites including at least Dodecanedioylcarnitine, Lysophosphatidylcholine, and Hexenoylcarnitine from said second sample taken from said second human patient. 
     
     
         18 . The system of  claim 12 , wherein said machine readable instructions are further configured to use a log-transformation to normalize said quantified metabolites. 
     
     
         19 . The system of  claim 12 , wherein said scale comprises at least a survival rate of said human patient from said pancreatic cancer. 
     
     
         20 . The system of  claim 12 , wherein said response to treatment comprises at least a viability of at least one treatment of said human patient for said pancreatic cancer.